In immune thrombocytopenia (ITP), a Phase 2 trial reported that mezagitamab materially increased platelet counts, providing a fresh clinical read-through for antibody-based options in a space where durable responses remain a high bar. The study evaluated the investigational antibody in patients with ITP and showed significant platelet count improvements. ITP is an autoimmune disorder characterized by low platelet levels due to increased destruction and impaired production. By directly targeting disease biology, mezagitamab is positioned as a potential therapy where response durability and safety profiles could differentiate it from existing treatments. The Phase 2 outcomes also add to the growing pipeline emphasis on earlier control of platelet loss, which can reduce bleeding risk and lessen reliance on steroids or rescue interventions. Sponsors are likely to focus on both magnitude and durability of platelet response as they design subsequent registrational studies. For investors and clinicians, the headline is the availability of a clinically meaningful biomarker outcome—platelet count—as the trial endpoint driving next-step development decisions.